Products

This offer is only addressed to countries/markets not covered by patent rights in force


Products with dossier ready & registered in EU

Lenalidomide

Form: capsules
Strenghts: 2.5mg, 5mg, 7.5mg, 10mg, 15mg, 20mg, 25mg
Field: oncology
Mechanism of action: immunomodulator
Indication: multiple myeloma
Patent expiry: March 2022
Products under development

Enzalutamide

Form: capsules
Strenghts: 40mg
Field: oncology
Mechanism of action: androgen receptor inhibitor
Indication: metastatic castration-resistant prostate cancer
Patent expiry: August 2027